Halozyme is not holding back against Merck & Co. in the companies' injectable Keytruda patent dispute, having now escalated a ...

California-based biotech Halozyme Therapeutics (Nasdaq: HALO) yesterday revealed it has filed a patent infringement lawsuit ...

A biotech company is suing to block Merck & Co. from launching an easier-to-use version of its blockbuster cancer treatment ...

Merck (MRK) stock trades flat as Halozyme Therapeutics (HALO) files patent infringement suit linked to MRK's new injectable ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), a biotechnology company that pioneered the use of human hyaluronidase ...

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data ...

Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. Read more about ...

MRK posts better-than-expected first-quarter results but trims its 2025 EPS outlook due to anticipated one-time charges.

With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...

Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...

- This May 1, 2018, shows Merck corporate headquarters in Kenilworth, N.J. RAHWAY, Nj – In its fourth quarter report, Merck, the giant pharmaceutical company with multiple facilities in eastern ...